Neovacs, a leading biotechnology company in the development of anti-cytokine and anti-protein viral regulation therapeutic vaccines to treat certain cancers and inflammatory diseases, announced that it had begun a phase I/II clinical study at three study centres in South Africa with the candidate TNF
Navigation
Daily News
- Undiagnosed Celiac Disease More Common Today Than 50 Years Ago Say US Researchers
- More Women Seek Nonprescription Remedies For Menopause Symptoms
- Flu Virus Ill-Suited For Rapid Transmission, But Researchers Say New Strain Bears Watching, Could Mutate
- Number Of Abortion Procedures Continues To Decline In Minnesota And Wisconsin
- Major new e-science resource for biologists
Translator
 |  |  |  |  |  |  |  |  |  |
 |  |  |  |  |  |  |  |  |  |
 |  |  |  |  |  |  |  |  |  |
 |  |  |  |  |  |  |  |  |  |
 |  | ||||||||
| By N2H | |||||||||